NEW YORK--(BUSINESS WIRE)--Feb. 23, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today dosing of the first patient in a phase I/II trial with ZIO-201, the Company’s proprietary alkylating drug. The study will take place at leading cancer centers in the U.S. and the U.K., including The University of Texas M. D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Michigan and the Royal Marsden Hospital.
